Wen, P. Y., Stein, A., van den Bent, M., De Greve, J., Wick, A., de Vos, F. Y. F. L., von Bubnoff, N., van Linde, M. E., Lai, A., Prager, G. W., Campone, M., Fasolo, A., Lopez-Martin, J. A., Kim, T. M., Mason, W. P., Hofheinz, R., Blay, J., Cho, D. C., Gazzah, A., Pouessel, D., Yachnin, J., Boran, A., Burgess, P., Ilankumaran, P., Gasal, E., & Subbiah, V. (2022). dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. Lancet oncology, 23(1), 53–64. http://access.bl.uk/ark:/81055/vdc_100148165972.0x00000d